223 related articles for article (PubMed ID: 25582950)
1. Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H; Killoran RC; Brickenden A; Fan J; Yang D; Choy WY
Biochem J; 2015 Apr; 467(1):141-51. PubMed ID: 25582950
[TBL] [Abstract][Full Text] [Related]
2. Fuzzy complex formation between the intrinsically disordered prothymosin α and the Kelch domain of Keap1 involved in the oxidative stress response.
Khan H; Cino EA; Brickenden A; Fan J; Yang D; Choy WY
J Mol Biol; 2013 Mar; 425(6):1011-27. PubMed ID: 23318954
[TBL] [Abstract][Full Text] [Related]
3. Molecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosis.
Stępkowski TM; Kruszewski MK
Free Radic Biol Med; 2011 May; 50(9):1186-95. PubMed ID: 21295136
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.
Padmanabhan B; Tong KI; Ohta T; Nakamura Y; Scharlock M; Ohtsuji M; Kang MI; Kobayashi A; Yokoyama S; Yamamoto M
Mol Cell; 2006 Mar; 21(5):689-700. PubMed ID: 16507366
[TBL] [Abstract][Full Text] [Related]
5. Microsecond molecular dynamics simulations of intrinsically disordered proteins involved in the oxidative stress response.
Cino EA; Wong-ekkabut J; Karttunen M; Choy WY
PLoS One; 2011; 6(11):e27371. PubMed ID: 22125611
[TBL] [Abstract][Full Text] [Related]
6. [Prothyomosin alpha interaction with KEAP1 doesn't lead to prothymosin alpha ubiquination and degradation].
Mel'nikov SV; Evstaf'eva AG; Vartapetian AB
Mol Biol (Mosk); 2007; 41(5):868-75. PubMed ID: 18240569
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
8. Structural and Dynamic Characterization of Mutated Keap1 for Varied Affinity toward Nrf2: A Molecular Dynamics Simulation Study.
Cheng IC; Chen YJ; Ku CW; Huang YW; Yang CN
J Chem Inf Model; 2015 Oct; 55(10):2178-86. PubMed ID: 26348991
[TBL] [Abstract][Full Text] [Related]
9. Activation of the Nrf2/ARE pathway via S-alkylation of cysteine 151 in the chemopreventive agent-sensor Keap1 protein by falcarindiol, a conjugated diacetylene compound.
Ohnuma T; Nakayama S; Anan E; Nishiyama T; Ogura K; Hiratsuka A
Toxicol Appl Pharmacol; 2010 Apr; 244(1):27-36. PubMed ID: 20026152
[TBL] [Abstract][Full Text] [Related]
10. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
Hayes JD; McMahon M
Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
[TBL] [Abstract][Full Text] [Related]
11. KEAP1 Cancer Mutants: A Large-Scale Molecular Dynamics Study of Protein Stability.
Wilson CJ; Chang M; Karttunen M; Choy WY
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065616
[TBL] [Abstract][Full Text] [Related]
12. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
Cheng L; Wang H; Li S; Liu Z; Wang C
Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
[TBL] [Abstract][Full Text] [Related]
13. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.
Lo SC; Li X; Henzl MT; Beamer LJ; Hannink M
EMBO J; 2006 Aug; 25(15):3605-17. PubMed ID: 16888629
[TBL] [Abstract][Full Text] [Related]
14. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
15. Binding of Disordered Peptides to Kelch: Insights from Enhanced Sampling Simulations.
Do TN; Choy WY; Karttunen M
J Chem Theory Comput; 2016 Jan; 12(1):395-404. PubMed ID: 26636721
[TBL] [Abstract][Full Text] [Related]
16. Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications for expression of oxidative stress-protecting genes.
Karapetian RN; Evstafieva AG; Abaeva IS; Chichkova NV; Filonov GS; Rubtsov YP; Sukhacheva EA; Melnikov SV; Schneider U; Wanker EE; Vartapetian AB
Mol Cell Biol; 2005 Feb; 25(3):1089-99. PubMed ID: 15657435
[TBL] [Abstract][Full Text] [Related]
17. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model.
Tong KI; Katoh Y; Kusunoki H; Itoh K; Tanaka T; Yamamoto M
Mol Cell Biol; 2006 Apr; 26(8):2887-900. PubMed ID: 16581765
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1.
Wu JH; Miao W; Hu LG; Batist G
Chem Biol Drug Des; 2010 May; 75(5):475-80. PubMed ID: 20486933
[TBL] [Abstract][Full Text] [Related]
19. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.
Ohta T; Iijima K; Miyamoto M; Nakahara I; Tanaka H; Ohtsuji M; Suzuki T; Kobayashi A; Yokota J; Sakiyama T; Shibata T; Yamamoto M; Hirohashi S
Cancer Res; 2008 Mar; 68(5):1303-9. PubMed ID: 18316592
[TBL] [Abstract][Full Text] [Related]
20. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
